#Switzerland #Heart Failure #Zug #Berlin Heals #C-MIC

Berlin Heals Raises Over 10 Million USD for Heart Failure Innovation

On February 12, 2026, Berlin Heals Holding AG, a forward-thinking MedTech firm focused on revolutionary heart failure therapies, announced that it has successfully closed a funding round securing over 10 million USD. This financing was sourced from both existing shareholders and new investors, marking a significant step in the company’s mission to enhance cardiac care.

The funds will primarily be allocated towards advancing their innovative cardiac microcurrent technology, known as C-MIC (Cardiac Microcurrent). This technology utilizes an implantable device designed to improve heart function through a proprietary method that delivers a constant electrical microcurrent to the heart. The device is already showing promising clinical outcomes, and Berlin Heals aims to bolster this evidence by sharing updated clinical data at significant cardiology conferences over the year.

In this latest phase of their development, Berlin Heals is focused on refining their implantation techniques to make them less invasive and their device designs more elegant and user-friendly. The raised funds will help expand the technology’s indications, facilitating access for a broader range of patients, and support the initiation of larger, randomized double-blinded clinical trials. These trials are crucial in preparing for an FDA Investigational Device Exemption (IDE) submission, a significant milestone for any MedTech company.

The company's dedication to addressing patients with dilated cardiomyopathy—a form of heart failure—has led to sustained improvements in both functionality and quality of life for those treated with the C-MIC device. Long-term follow-up data from their early studies provided compelling support for the durability of this innovative therapy, reinforcing confidence in their clinical and regulatory goals.

Chief Executive Officer John Brumfield expressed the importance of this funding, stating, "Closing this financing round marks an important milestone for us. Our gratitude goes to our Co-Founder Marko Bagaric for his unwavering support and vision. This funding fortifies our path toward less invasive solutions that could greatly enhance the reach and impact of our therapy."

Rob ten Hoedt, the Board Chairman of Berlin Heals, also highlighted the pressing need in heart failure treatment, asserting, "Heart failure represents a significant unmet medical necessity. Having observed Berlin Heals’ growth, I strongly believe that our technology has the potential to completely redefine the way we treat heart failure patients. The financing enables us to convert our innovation into accessible therapy, capable of influencing the quality of life for many more patients across the globe."

Established in 2014, Berlin Heals Holding AG continues to lead innovation in cardiac technology, with the potential to redefine the approach to patient care in heart failure management significantly. This new funding aligns with the company's overarching mission to save and enhance lives through advanced medical solutions. As they prepare to validate their technology with rigorous research and trials, the eyes of the medical community will undoubtedly be on Berlin Heals, waiting to see how far their innovations can extend the horizons of heart failure treatment.